Daniel Bensen - Sep 17, 2021 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Operating Officer
Signature
s/ John Healy, Attorney-in Fact
Stock symbol
TYRA
Transactions as of
Sep 17, 2021
Transactions value $
$0
Form type
4
Date filed
9/17/2021, 04:48 PM
Previous filing
Sep 14, 2021
Next filing
Nov 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Conversion of derivative security +8.5K +1.64% 528K Sep 17, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Series A Preferred Stock Conversion of derivative security $0 -3.27K -100% $0.00* 0 Sep 17, 2021 Common Stock 8.5K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.